Intelligence / Healthtech / New Clinical Trials / Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc.
29 Oct 2026: Trial registered · Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 29 Oct 2026
- Title
- Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Conditions
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07904806
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Otsuka Pharmaceutical Development & Commercialization, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Otsuka Pharmaceutical Development & Commercialization, Inc. in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.